Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."


TSX:TTH - Post by User

Post by deninsaskon Aug 23, 2007 2:16pm
120 Views
Post# 13291344

"Excellence In Clinical Research Award"

"Excellence In Clinical Research Award" While we wait for some of the NR's of Transitions latest accomplishments I've decided to post a few oldies for our US listing TTHI cousins........enjoy. Once again Congrats Dr. Brand, Dr. Cruz and Dr. Rabinovitch on your "Excellence in Clinical Research Awards" from the JDRF showcasing your extraordinary individual efforts in bringing E1-INT to this stage of Clinical Development. https://www.jdrf.org/index.cfm?fuseaction=home.viewPage&page_id=E3C018FF-1279-D3DC-F9A9A743B3B18978 A very bright future for this E1-INT technology awaits Further Clinical Development and the Extraordinarily Positive Data recently announced reinforces the strong commitment made by Transition Therapeutics to make Beta Cell Regeneration a Reality. With G1 (Gastrin) (the INT in E1-INT) moving to IT'S OWN Stand Alone Phasell Clinical Trial very soon and E1-INT moving forward to Phasellb Clinical Trials this year as well, the future certainly is looking very very bright for the Gastrin Based Technology these awards are based on!!
Bullboard Posts